酪蛋白激酶1是慢性淋巴细胞白血病的治疗靶点
本研究探讨抑制CK1δ/ε对原代慢性淋巴细胞白血病(CLL)细胞的作用,并在两种基于Eµ-TCL1小鼠的白血病模型中评估CK1δ/ε抑制剂PF-670462的体内疗效。结果显示PF-670462阻断微环境相互作用,延缓白血病细胞积累并预防贫血,延长总生存期,且与依鲁替尼联用具有协同效应。
要点
- CK1δ/ε抑制剂PF-670462可阻断所有主要CLL亚型原代细胞的趋化、侵袭及与基质细胞通讯。
- 小鼠模型中CK1抑制延缓外周血和脾脏白血病细胞积累并预防贫血发生,显著延长总生存期。
- CK1抑制在体外与BCR抑制剂(如依鲁替尼)协同,在体内显著改善依鲁替尼疗效。
核心结论
- CK1δ/ε抑制剂PF-670462的临床前测试表明CK1可能作为CLL的新型治疗靶点,与BCR抑制剂发挥协同作用。
- 靶向CK1可为基于BCR信号和抗凋亡信号(BCL-2)抑制的治疗策略提供替代或补充。
研究设计与样本
- 研究检测CK1δ/ε抑制剂PF-670462对原代CLL细胞的影响,并使用两种基于Eµ-TCL1诱导白血病的鼠模型(同基因过继转移模型和自发疾病发展模型)分析体内治疗潜力。
主要发现
- PF-670462显著阻断所有主要CLL亚型原代CLL细胞的微环境相互作用(趋化、侵袭及与基质细胞通讯)。
- 小鼠模型中CK1抑制减缓外周血和脾脏白血病细胞积累并预防贫血发生,PF-670462治疗导致总生存期显著延长。
- CK1抑制在体外与依鲁替尼等BCR抑制剂具有协同效应,在体内显著改善依鲁替尼效果。
- PF-670462与依鲁替尼联合治疗的小鼠在停药后疾病进展最慢,且与仅用依鲁替尼治疗相比生存期显著更长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Casein kinase 1δ/ε (CK1δ/ε) is a key component of noncanonical Wnt signaling pathways, which were shown previously to drive pathogenesis of chronic lymphocytic leukemia (CLL). In this study, we investigated thoroughly the effects of CK1δ/ε inhibition on the primary CLL cells and analyzed the therapeutic potential in vivo using 2 murine model systems based on the Eµ-TCL1-induced leukemia (syngeneic adoptive transfer model and spontaneous disease development), which resembles closely human CLL. We can demonstrate that the CK1δ/ε inhibitor PF-670462 significantly blocks microenvironmental interactions (chemotaxis, invasion and communication with stromal cells) in primary CLL cells in all major subtypes of CLL. In the mouse models, CK1 inhibition slows down accumulation of leukemic cells in the peripheral blood and spleen and prevents onset of anemia. As a consequence, PF-670462 treatment results in a significantly longer overall survival. Importantly, CK1 inhibition has synergistic effects to the B-cell receptor (BCR) inhibitors such as ibrutinib in vitro and significantly improves ibrutinib effects in vivo. Mice treated with a combination of PF-670462 and ibrutinib show the slowest progression of disease and survive significantly longer compared with ibrutinib-only treatment when the therapy is discontinued. In summary, this preclinical testing of CK1δ/ε inhibitor PF-670462 demonstrates that CK1 may serve as a novel therapeutic target in CLL, acting in synergy with BCR inhibitors. Our work provides evidence that targeting CK1 can represent an alternative or addition to the therapeutic strategies based on BCR signaling and antiapoptotic signaling (BCL-2) inhibition.
引用
- Janovska P, Verner J, Kohoutek J, et al. Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood. 2018. PMID: 29317454. doi:10.1182/blood-2017-05-786947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。